Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European …

Tyrosine kinase inhibitors (TKIs) exemplify the success of molecular targeted therapy for
chronic myeloid leukemia (CML). However, some patients do not respond to TKI therapy …

The prognostic relevance of additional cytogenetic findings at diagnosis of chronic myeloid
leukemia (CML) is unclear. The impact of additional cytogenetic findings at diagnosis on …

Additional chromosomal abnormalities (ACAs) in Philadelphia-positive cells have been
reported in∼ 5% of patients with newly diagnosed chronic myeloid leukemia (CML) in …

Chronic myeloid leukemia (CML) has been the first human malignancy to be associated,
more than 50 years ago, with a consistent chromosomal abnormality—the t (9; 22)(q34; q11) …

Simple Summary Myeloma is a hematological cancer characterized by numerous genetic
abnormalities currently identified using fluorescent in situ hybridization (FISH). However …

Chronic Myeloid Leukemia (CML) is a rare malignant proliferative disease of the
hematopoietic system, whose molecular hallmark is the Philadelphia chromosome (Ph). The …

Abstract Objective and Background Chronic myeloid leukemia (CML) is a neoplastic disease
whose genetic and cytogenetic changes play important roles in prognosis and treatment …

The high fatality of patients with blast phase (BP) chronic myeloid leukemia (CML)
necessitates identification of high-risk (HR) patients to prevent onset of BP. Here, we …

The introduction of tyrosine kinase inhibitors (TKI) in the treatment of Philadelphia
chromosome-positive (Ph+) chronic myeloid leukemia (CML) has revolutionized the …